GlassScriptPhysician profile
Andrew G Horodner
NPI 1386849974
$2,681.70
in general payments reported to CMS, 2019-2025
25 companies · $513 in 2025
The $513 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $91.54 · 2022: $179 · 2023: $805 · 2024: $944 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,130 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.12 |
| Education | $131.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $526.17 | 2022-2025 | Calquence |
| Genentech USA, INC. | $315.57 | 2019-2025 | Tecentriq, Venclexta |
| Pfizer INC. | $269.60 | 2022-2024 | |
| Seagen INC. | $228.19 | 2022-2023 | Tukysa |
| Genzyme Corporation | $168.60 | 2023-2024 | |
| Medtronic, INC. | $155.41 | 2024 | Ligasure |
| Puma Biotechnology, INC. | $129.98 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $111.95 | 2021-2025 | |
| Array Biopharma INC | $107.62 | 2023-2024 | Tukysa, Mektovi, Braftovi |
| Incyte Corporation | $89.00 | 2023 | |
| Glaxosmithkline, LLC. | $80.89 | 2023-2024 | Jemperli, Zejula |
| Janssen Biotech, INC. | $71.17 | 2023-2025 | Erleada, Balversa, Akeega |
| Merck Sharp & Dohme LLC | $68.22 | 2023-2025 | Keytruda, Welireg |
| Recordati_rare_diseases_inc. | $58.43 | 2025 | Sylvant, Enjaymo |
| Eisai INC. | $55.29 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48.40 | 2023-2024 | |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Ge Healthcare | $30.85 | 2025 | |
| Stemline Therapeutics INC. | $30.48 | 2023-2024 | Orserdu |
| Springworks Therapeutics, INC. | $28.57 | 2024 | Ogsiveo |
| Spectrum Pharmaceuticals INC. | $21.83 | 2024 | Rolvedon |
| Morphosys, US INC. | $18.92 | 2022 | |
| Kite Pharma, INC. | $12.79 | 2023 | |
| Tactile Systems Technology INC | $11.77 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Horodner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.